Law360, New York (August 12, 2008, 12:00 AM ET) -- A unit of generics maker Barr Pharmaceuticals Inc. struck deals with Boehringer Ingelheim that should resolve patent suits over the stroke prevention treatment Aggrenox and the restless leg syndrome drug Mirapex, and allow Barr to launch copycat versions of the drugs before Boehringer's patents expire.
Barr Laboratories Inc. signed settlement agreements covering both drugs, and another Barr subsidiary, Duramed Pharmaceuticals, entered into a co-promotion deal with Boehringer covering Aggrenox, Barr Pharmaceuticals said Tuesday.
The agreements should resolve two patent suits in the U.S. District Court for...
Barr Settles Mirapex, Aggrenox Patent Suits
To view the full article, take a free trial now.
